NEOGENOMICS INC (NEO) Forecast, Price Target & Analyst Ratings
NASDAQ:NEO • US64049M2098
8.83 USD
-0.09 (-1.01%)
Last: Mar 10, 2026, 02:05 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for NEOGENOMICS INC (NEO).
Forecast Snapshot
Consensus Price Target
$14.11
+ 59.80% Upside
Next Earnings Forecast
Release DateApr 27, 2026
PeriodQ1 / 2026
EPS Estimate$0.01
Revenue Estimate186.35M
ChartMill Buy Consensus
72.22%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$14.11
Upside
+ 59.80%
From current price of $8.83 to mean target of $14.11, Based on 18 analyst forecasts
Low
$7.07
Median
$15.30
High
$17.85
Price Target Revisions
1 Month
2.47%
3 Months
12.16%
Price Target Summary
18 Wall Street analysts provided a forecast for the next 12 months for NEO. The average price target is 14.11 USD. This implies a price increase of 59.8% is expected in the next year compared to the current price of 8.83.
The average price target has been revised upward by 12.16% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
72.22%
NEO was analyzed by 18 analysts. The buy percentage consensus is at 72. So analysts seem to be have mildly positive about NEO.
In the previous month the buy percentage consensus was at a similar level.
NEO was analyzed by 18 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-02-24 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2026-02-17 | Needham | Maintains | Buy -> Buy |
| 2026-01-12 | Needham | Reiterate | Buy -> Buy |
| 2025-09-12 | TD Cowen | Maintains | Buy -> Buy |
| 2025-09-02 | Stephens & Co. | Maintains | Overweight -> Overweight |
| 2025-08-29 | Needham | Maintains | Buy -> Buy |
| 2025-08-04 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-07-30 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2025-07-29 | William Blair | Downgrade | Outperform -> Market Perform |
| 2025-07-29 | Needham | Maintains | Buy -> Buy |
| 2025-05-06 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-05-01 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2025-04-30 | Leerink Partners | Downgrade | Outperform -> Market Perform |
| 2025-04-30 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-04-29 | Needham | Maintains | Buy -> Buy |
| 2025-04-17 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-02-26 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-02-19 | Needham | Maintains | Buy -> Buy |
| 2025-02-19 | B of A Securities | Maintains | Neutral -> Neutral |
| 2025-01-28 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-01-16 | Benchmark | Reiterate | Hold -> Hold |
| 2025-01-15 | Needham | Reiterate | Buy -> Buy |
| 2025-01-13 | Benchmark | Downgrade | Buy -> Hold |
| 2025-01-10 | Needham | Reiterate | Buy -> Buy |
| 2024-12-13 | B of A Securities | Maintains | Neutral -> Neutral |
Next Earnings Forecast Details
Next Earnings Details
Release DateApr 27, 2026
PeriodQ1 / 2026
EPS Estimate$0.01
Revenue Estimate186.35M
Revenue Q2Q10.90%
EPS Q2QN/A
Number of Analysts14
Next Earnings Revisions
Revenue (1 Month)
-1.54%
Revenue (3 Months)
-1.72%
EPS (1 Month)
-39.86%
EPS (3 Months)
-12.50%
Next Earnings Summary
NEO is expected to report earnings on 4/27/2026. The consensus EPS estimate for the next earnings is 0.01 USD and the consensus revenue estimate is 186.35M USD.
The next earnings revenue estimate has been revised downward by 1.72% in the past 3 months.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 591.643M 16.08% | 660.566M 11.65% | 727.332M 10.11% | 804.64M 10.63% | 882.96M 9.73% | 963.4M 9.11% | 1.035B 7.43% | 1.118B 8.02% | |
| EBITDA YoY % growth | -24.065M 71.24% | -12.901M 46.39% | -20.304M -57.38% | 55.796M 374.80% | 76.886M 37.80% | 100.25M 30.39% | 140.29M 39.94% | N/A | |
| EBIT YoY % growth | -96.648M 36.87% | -85.448M 11.59% | -88.128M -3.14% | -56.401M 36.00% | -41.577M 26.28% | -18.659M 55.12% | -30.704M -64.55% | -9.09M 70.39% | |
| Operating Margin | -16.34% | -12.94% | -12.12% | -7.01% | -4.71% | -1.94% | -2.97% | -0.81% | |
| EPS YoY % growth | -0.11 80.36% | 0.10 190.91% | 0.12 20.00% | 0.17 39.26% | 0.32 90.03% | 0.45 41.16% | 0.63 39.69% | 0.82 30.65% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | Q1 / 28 | Q2 / 28 | Q3 / 28 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 0.01 | 0.04 24.87% | 0.05 73.11% | 0.07 10.95% | 0.05 485.14% | 0.09 143.73% | 0.11 103.81% | 0.12 73.27% | 0.07 36.72% | 0.10 10.62% | 0.15 43.13% |
| Revenue Q2Q % growth | 186.35M 10.90% | 198.34M 9.38% | 206.67M 10.05% | 208.21M 9.49% | 203.45M 9.18% | 220.51M 11.18% | 228.41M 10.52% | 232.21M 11.53% | 222.3M 9.27% | 241.29M 9.42% | 250.68M 9.75% |
| EBITDA Q2Q % growth | 8.756M 186.72% | 12.757M 72.28% | 15.244M -51.61% | 16.187M -70.59% | 16.067M 83.50% | 21.643M 69.66% | 24.513M 60.80% | 24.414M 50.82% | N/A | N/A | N/A |
| EBIT Q2Q % growth | -19.381M 30.35% | -15.403M 44.17% | -16.683M 16.29% | -15.971M -24.89% | -20.881M -7.74% | -13.763M 10.64% | -10.039M 39.82% | -10.423M 34.74% | N/A | N/A | N/A |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
55.16%
EPS Next 5 Year
46.80%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
9.56%
Revenue Next 5 Year
8.82%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
42.58%
EBIT Next 5 Year
34.35%
NEOGENOMICS INC / NEO Forecast FAQ
What is the price target for NEO stock?
18 analysts have analysed NEO and the average price target is 14.11 USD. This implies a price increase of 59.8% is expected in the next year compared to the current price of 8.83.
What is the next earnings date for NEO stock?
NEOGENOMICS INC (NEO) will report earnings on 2026-04-27, before the market open.
What are the consensus estimates for NEOGENOMICS INC (NEO) next earnings?
The consensus EPS estimate for the next earnings of NEOGENOMICS INC (NEO) is 0.01 USD and the consensus revenue estimate is 186.35M USD.
What is the consensus rating for NEO stock?
The consensus rating for NEOGENOMICS INC (NEO) is 72.2222 / 100 . This indicates that analysts generally have a positive outlook on the stock.